1. Jakobsen, JC, Katakam, KK, Schou, A et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 2017;17:58.
3. Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
4. Hamilton, M. The Hamilton Depression Scales. In: Sartorius N, Ban TA, editors. Assessment of Depression. Berlin, Germany: Springer, 1986.
5. Bech, P. Clinical Psychometrics. Oxford, UK: Wiley-Blackwell, 2012.
6. Bech, P, Gram, LF, Dein, E, Jacobsen, O, Vitger, J, Bolwig, TG. Quantitative rating of depressive states. Acta Psychiatr Scand 1975;51:161–170.
7. Bech, P, Allerup, P, Gram, LF et al. The Hamilton Depression Scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981;63:290–299.
8. Ostergaard, SD, Bech, P, Trivedi, MH, Wisniewski, SR, Rush, AJ, Fava, M. Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the Research Domain Criteria (RDoC). J Affect Disord 2014;163:18–24.
9. Ostergaard, SD, Meyers, BS, Flint, AJ et al. Measuring psychotic depression. Acta Psychiatr Scand 2014;129:211–220.
10. Ostergaard, SD, Bech, P, Miskowiak, KW. Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton Melancholia Subscale (HAM-D(6)) as outcome measure. J Affect Disord 2016;190:842–845.
11. Licht, RW, Qvitzau, S, Allerup, P, Bech, P. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand 2005;111:144–149.
12. Bech, P, Fava, M, Trivedi, MH, Wisniewski, SR, Rush, AJ. Factor structure and dimensionality of the two depression scales in STAR*D using level 1 datasets. J Affect Disord 2011;132:396–400.
13. Martiny, K, Refsgaard, E, Lund, V et al. The day-to-day acute effect of wake therapy in patients with major depression using the HAM-D6 as primary outcome measure: results from a randomised controlled trial. PLoS One 2013;8:e67264.
14. Kyle, PR, Lemming, OM, Timmerby, N, Sondergaard, S, Andreasson, K, Bech, P. The validity of the different versions of the Hamilton Depression Scale in separating remission rates of placebo and antidepressants in clinical trials of major depression. J Clin Psychopharmacol 2016;36:453–456.
15. Korner, A, Lauritzen, L, Abelskov, K et al. Rating scales for depression in the elderly: external and internal validity. J Clin Psychiatry 2007;68:384–389.
16. Bagby, RM, Ryder, AG, Schuller, DR, Marshall, MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry 2004;161:2163–2177.
17. Bech, P, Cialdella, P, Haugh, MC et al. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000;176:421–428.
18. Hieronymus, F, Emilsson, JF, Nilsson, S, Eriksson, E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 2016;21:523–530.
19. Bech, P, Kajdasz, DK, Porsdal, V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology (Berl) 2006;188:273–280.
20. Bech, P, Boyer, P, Germain, JM et al. HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder. Pharmacopsychiatry 2010;43:271–276.
21. Bech, P. Applied psychometrics in clinical psychiatry: the pharmacopsychometric triangle. Acta Psychiatr Scand 2009;120:400–409.
22. Bech, P, Fava, M, Trivedi, MH, Wisniewski, SR, Rush, AJ. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 2012;125:342–348.
23. Bech, P, Gefke, M, Lunde, M, Lauritzen, L, Martiny, K. The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: a double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes. Depress Res Treat 2011;2011:806298.
24. Papakostas, GI, Ostergaard, SD, Iovieno, N. The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry 2015;76:456–466.
25. Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
26. Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
27. Bech, P, Allerup, P, Larsen, ER, Csillag, C, Licht, RW. The Hamilton Depression Scale (HAM-D) and the Montgomery-Asberg Depression Scale (MADRS). A psychometric re-analysis of the European genome-based therapeutic drugs for depression study using Rasch analysis. Psychiatry Res 2014;217:226–232.
28. Bouman, TK, Kok, AR
. Homogeneity of Beck’s Depression Inventory (BDI): applying Rasch analysis in conceptual exploration. Acta Psychiatr Scand 1987;76:568–573.